PSD502 Tempe Spray reports another positive pivotal Phase III study
Updated Aug 17, 2009 at 13:14 EST.
Schiele Pharma Inc. and Plethora Solutions PLC reported another positive phase III study of PSD502, the Premature Ejaculation ( PE ) . This is another major milestone on the road for regulatory approvals around the world. The spray, applied just 5 minutes before intercourse is an excellent on demand treatment for PE. Results of the clinical studies are encouraging and combined with the recent approval of Priligy, and Oral on demand treatment for
PE,
PE patients will now have a set of treatment choices for the condition.
The PEhomepage team will continue to update its readers
